Chronic aspirin via dose-dependent and selective inhibition of cardiac proteasome possibly contributed a potential risk to the ischemic heart

Experimental Gerontology

Volumn 48, Issue 8, 2013, Pages 812-823

  Tan, Chunjiang ^a   Chen, Wenlie ^a   Wu, Yanbin ^a   Lin, Jiumao ^a   Lin, Ruhui ^a   Tan, Xuerui ^b   Chen, Songming ^b  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANTOU UNIVERSITY   (China)

Author keywords

A potential risk; Aspirin; Cardiac proteasome; Ischemic rat heart; Selective inhibition

Indexed keywords

ACETYLSALICYLIC ACID; LYSINE ACETYLSALICYLATE; PROTEASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UBIQUITINATION;

A POTENTIAL RISK; ASPIRIN; CARDIAC PROTEASOME; ISCHEMIC RAT HEART; SELECTIVE INHIBITION;

ANIMALS; ASPIRIN; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS;

RATTUS;

EID: 84879532008     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.03.012     Document Type: Article

References (65)

1. Agnetti G., Bordoni A., Angeloni C., Leoncini E., Guarnieri C., Caldarera C.M., Biagi P.L., Hrelia S. Green tea modulation of inducible nitric oxide synthase in hypoxic/reoxygenated cardiomyocytes. Biochimie 2005, 87:457-460.
2. Al-Khadra A.S., Salem D.N., Rand W.M., Scazziota A., Turpie A.G.G. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J. Am. Coll. Cardiol. 1998, 31:419-425.
3. Altman R., Rouvier J., Gurfinkel E., Scazziota A., Turpie A.G.G. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant. Circulation 1996, 94:2113-2116.
4. Andrew T.C., Shuji O., Charles S.F. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 2007, 356:2131-2142.
5. Antman E.M., DeMets D., Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005, 112:759-770.
6. Arstall M.A., Zhao Y.Z., Hornberger L., Kennedy S.P., Buchholz R.A., Osathanondh R., Kelly R.A. Human ventricular myocytes in vitro exhibit both early and delayed preconditioning responses to simulated ischemia. J. Mol. Cell. Cardiol. 1998, 30:1019-1025.
7. Berger J.S., Krantz M.J., Kittelson J.M., Hiatt W.R. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009, 301:1909-1919.
8. Bochtler M., Ditzel L., Groll M., Huber R. The proteasome. Annu. Rev. Biophys. Biomol. Struct. 1999, 28:295-317.
9. Brummelkamp T.R., Nijman S.M., Dirac A.M., Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-?B. Nature 2003, 424:797-801.
10. Bulteau A.L., Lundberg K.C., Humphries K.M., Sadek H.A., Szweda P.A., Friguet B., Szweda L.I. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 2001, 276:30057-30063.
11. Calverley D., Roth G. Aspirin, prostaglandins and platelet function: pharmacology and thrombosis prevention. Handbook of Platelet Physiology and Pharmacology 1999, 478-494. Kluwer Academic Publishers, Norwell, MA. G. Rao (Ed.).
12. Cappelleri J.C., Lau J., Kupelnick B., Chalmers T.C. Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients: a meta regression analysis. Online J. Curr. Clin. Trials 1995, 14:174.
13. Chu-Ping M., Vu J.H., Proske R.J., Slaughter C.A., DeMartino G.N. Identification, purification, and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20S proteasome. J. Biol. Chem. 1994, 269:3539-3547.
14. Cleland J.G. Chronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse?. Nat. Clin. Pract. Cardiovasc. Med. 2006, 3:234-235.
15. Cleland J.G., Bulpitt C.J., Falk R.H., Findlay I.N., Oakley C.M., Murray G., Poole-Wilson P.A., Prentice C.R., Sutton G.C. Is aspirin safe for patients with heart failure?. Heart 1995, 74:215-219.
16. Dikshit P., Chatterjee M., Goswami A., Mishra A., Jana N.R. Aspirin induces apoptosis through the inhibition of proteasome function. J. Biol. Chem. 2006, 281:29228-29235.
17. Divald A., Powell S.R. Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic. Biol. Med. 2006, 40:156-164.
18. Drews O., Wildgruber R., Zong C., Sukop U., Nissum M., Weber G., Gomes A.V., Ping P. Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol. Cell. Proteomics 2007, 6:2021-2031.
19. Finley D., Chau V. Ubiquitination. Annu. Rev. Cell Biol. 1991, 7:25-69.
20. Fomovsky G.M., Holmes J.W. Evolution of scar structure, mechanics, and ventricular function after myocardial infarction in the rat. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H221-H228.
21. Frelinger A.L., Li Y.F., Linden M.D., Barnard M.R., Fox M.L., Christie D.J., Furman M.I., Michelson A.D. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009, 120:2586-2596.
22. Friguet B., Szweda L.I. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein. FEBS Lett. 1997, 405:21-25.
23. Fu H.Y., Minamino T., Tsukamoto O., Sawada T., Asai M., Kato H., Asano Y., Fujita M., Takashima S., Hori M., Kitakaze M. Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovasc. Res. 2008, 79:600-610.
24. Gaczynska M., Rock K.L., Spies T., Goldberg A.L. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. PNAS 1994, 91:9213-9217.
25. Gaczynska M., Goldberg A.L., Tanaka K., Hendil K.B., Rock K.L. Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7. J. Biol. Chem. 1996, 271:17275-17280.
26. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., Schramm T.K., Hansen M.L., Fosbøl E.L., Sorensen R., Folke F., Buch P., Gadsboll N., Rasmussen S., Poulsen H.E., Kober L., Madsen M., Torp-Pedersen C. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch. Intern. Med. 2009, 169:141-149.
27. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 2002, 82:373-428.
28. Gomes A.V., Zong C., Edmondson R.D., Berhane B.T., Wang G.W., Le S., Jones R.C., Thyparambil S., Wang G.W., Qiao X., Bardag-Gorce F., Ping P. Mapping the murine cardiac 26S proteasome complexes. Circ. Res. 2006, 99:362-371.
29. Gomes A.V., Young G.W., Wang Y., Zong C., Eghbali M., Drews O., Lu H., Stefani E., Ping P. Contrasting proteome biology and functional heterogeneity of the 20S Proteasome complexes in mammalian tissues. Mol. Cell. Proteomics 2009, 8:302-315.
30. Gronostajski R.M., Pardee A.B., Goldberg A.L. The ATP dependence of the degradation of short- and long-lived proteins in growing fibroblasts. J. Biol. Chem. 1985, 260:3344-3349.
31. Hacihanefioglu A., Tarkun P., Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. 2008, 88:219-222.
32. Hayden M., Pignone M., Phillips C., Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2002, 136:161-172.
33. Hedhli N., Lizano P., Hong C., Fritzky L.F., Dhar S.K., Liu H., Tian Y., Gao S., Madura K., Vatner S.F., Depre C. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1385-H1393.
34. Heindl B., Becker B.F. Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC58125, aggravates postischaemic cardiac dysfunction, independent of COX function. Naunyn Schmiedebergs Arch. Pharmacol. 2001, 363:233-240.
35. Heinemeyer W., Ramos P.C., Dohmen R.J. The ultimate nanoscale mincer: assembly, structure and active sites of the 20S proteasome core. Cell. Mol. Life Sci. 2004, 61:1562-1578.
36. Hershko A., Ciechanover A. The ubiquitin system for protein degradation. Annu. Rev. Biochem. 1992, 61:761-807.
37. Huang Y.C., Chuang L.Y., Hung W.C. Mechanisms underlying nonsteroidal anti-inflammatory drug-induced p27Kip1 expression. Mol. Pharmacol. 2002, 62:1515-1521.
38. Huang S., Patterson E., Yu X., Garrett M.W., De Aos I., Kem D.C. Proteasome inhibition 1h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1298-H1303.
39. Ishii T., Sakurai T., Usami H., Uchida K. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26S proteasome. Biochemistry 2005, 44:13893-13901.
40. Jennings R.B., Steenbergen J.C. Nucleotide metabolism and cellular damage in myocardial ischemia. Annu. Rev. Physiol. 1985, 47:727-749.
41. Jhund P.S., Davie A.P., McMurray J.J.V. Aspirin inhibits the acute vasodilator response to furosemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 2001, 37:1234-1238.
42. Jolly S.S., Pogue J., Haladyn K., Peters R.J.G., Fox K.A.A., Avezum A., Gersh B.J., Rupprecht H.J., Yusuf S., Mehta S.R. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur. Heart J. 2009, 30:900-907.
43. Kalkman E.A., van Suylen R.J., van Dijk J.P., Saxena P.R., Schoemaker R.G. Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat. J. Mol. Cell. Cardiol. 1995, 27:2483-2494.
44. Kisselev A.F., Akopian T.N., Woo K.M., Goldberg A.L. The sizes of peptides generated from protein by mammalian 26 and 20S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J. Biol. Chem. 1999, 274:3363-3371.
45. Kloβ A., Meiners S., Ludwig A., Dahlmann B. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc. Res. 2010, 85:367-375.
46. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265:956-959.
47. Krumholz H.M., Chen Y.T., Radford M.J. Aspirin and the treatment of heart failure in the elderly. Arch. Intern. Med. 2001, 161:577-582.
48. Liu J., Chen Q., Huang W., Horak K.M., Zheng H., Mestril R., Wang X. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J. 2006, 20:362-364.
49. Liu J., Tang M., Mestril R., Wang X. Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. J. Mol. Cell. Cardiol. 2006, 40:451-454.
50. Meune C., Mahó I., Mourad J.J., Cohen-Solal A., Levy B., Kevorkian J.P., Jondeau G., Habib A., Lebret M., Knellwolf A.L., Simoneau G., Caulin C., Bergmann J.F. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur. J. Heart Fail. 2003, 5:271-279.
51. Muller D.N., Heissmeyer V., Dechend R., Hampich F., Park J.K., Fiebeler A., Shagdarsuren E., Theuer J., Elger M., Pilz B., Breu V., Schroer K., Ganten D., Dietz R., Haller H., Scheidereit C., Luft F.C. Aspirin inhibits NF-kB and protects from angiotensin II-induced organ damage. FASEB J. 2001, 15:1822-1824.
52. Powell S.R., Wang P., Divald A., Teichberg S., Haridas V., McCloskey T.W., Davies K.J., Katzeff H. Aggregates of oxidized proteins (lipofuscin) induce apoptosis through proteasome inhibition and dysregulation of proapoptotic proteins. Free Radic. Biol. Med. 2005, 38:1093-1101.
53. Powell S.R., Wang P., Katzeff H., Shringarpure R., Teoh C., Khaliulin I., Das D.K., Davies K.J., Schwalb H. Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid. Redox Signal. 2005, 7:538-546.
54. Pye J., Ardeshirpour F., McCain A., Bellinger D.A., Merricks E., Adams J., Elliott P.J., Pien C., Fischer T.H., Baldwin A.S., Nichols T.C. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2003, 284:H919-H926.
55. Sarikas A., Carrier L., Schenke C., Doll D., Flavigny J., Lindenberg K.S., Eschenhagen T., Zolk O. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc. Res. 2005, 66:33-44.
56. Schoemaker R.G., Saxena P.R., Kalkman E.A.J. Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats. Cardiovasc. Res. 1998, 37:108-114.
57. Schwertner H.A., McGlasson D., Christopher M., Bush A.C. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations. Thromb. Res. 2006, 118:529-534.
58. Sijts A., Zaiss D., Kloetzel P.M. The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr. Mol. Med. 2001, 1:665-676.
59. Stangl K., Gunther C., Frank T., Lorenz M., Meiners S., Ropke T., Stelter L., Moobed M., Baumann G., Kloetzel P.M., Stangl V. Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochem. Biophys. Res. Commun. 2002, 291:542-549.
60. Stansfield W.E., Moss N.C., Willis M.S., Tang R., Selzman C.H. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann. Thorac. Surg. 2007, 84:120-125.
61. UK-TIA Study Group United Kingdom Transient Ischemic Attack (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatry 1991, 54:1044-1054.
62. Werf F.V., Ardissino D., Betriu A., Cokkinos D.V., Falk E., Fox K.A.A., Julian D., Lengyel M., Neumann F.J., Ruzyllo W., Thygesen C., Underwood S.R., Vahanian A., Verheugt F.W.A., Wijns W. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of acute myocardial infarction of the European Society of Cardiology. Eur. Heart J. 2003, 24:28-66.
63. Yang X.P., Liu Y.H., Rhaleb N.E., Kurihara N., Kim H.E., Carretero O.A. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am. J. Physiol. Heart Circ. Physiol. 1999, 277:H1967-H1974.
64. Young G.W., Wang Y., Ping P. Understanding proteasome assembly and regulation: importance to cardiovascular medicine. Trends Cadiovasc. Med. 2008, 3:93-98.
65. Zong C., Gomes A.V., Drews O., Li X., Young G.W., Berhane B., Qiao X., French S.W., Bardag-Gorce F., Ping P. Regulation of murine cardiac 20S proteasomes: role of associating partners. Circ. Res. 2006, 99:372-380.